Breast cancer genetics: unsolved questions and open perspectives in an expanding clinical practice.
Breast cancer is the most common cause of cancer death in the United Kingdom, with a lifetime risk of one in nine in women. Only 5-10% of all cancers is thought to be due to strongly penetrant inherited predisposing genes, such as BRCA1 and BRCA2. However, other less penetrant genes, including some autosomal recessive genes, are likely to be of etiological importance in other families. This review addresses the current knowledge of breast cancer susceptibility genes and explores the possibilities for future developments. Features of tumor pathology, prognosis, and the scope for targeted treatments in mutation carriers are discussed, and the management of known carriers and those at increased risk for developing breast cancer are evaluated. Genetic testing for cancer susceptibility may become widely available in the future, and has important ethical and management implications.
Hodgson
Shirley V
SV
Department of Clinical Development Sciences, St. George's Hospital Medical School, Cranmer Terrace, London SW19 0RE, UK. s.hodgson@sghms.ac.uk
Morrison
Patrick J
PJ
Irving
Melita
M
D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D016158:Genes, p53; D020022:Genetic Predisposition to Disease; D006801:Humans; D019683:Penetrance; D011110:Polymorphism, Genetic / Q000235:genetics; D018570:Risk Assessment